2026-04-29T08:12:45Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/100902025-05-27T12:58:46Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19612

00925njm 22002777a 4500 dc Imaz-Iglesia, Iñaki author Rubio-Gonzalez, Beltran author Cornejo, Ana M author Gonzalez-Enriquez, Jesus author 2014-04 Rotavirus is not included in the Spanish mass infant vaccination schedule but has also not been economically evaluated for its inclusion. We analysed cost-utility of the universal infant rotavirus vaccination using RotaTeq® versus no vaccination in Spain. We also carried out a budget impact analysis and determined the effect on results of different variables introduced in the model. A deterministic Markov model was built considering loss of quality of life for children and their parents, and introducing direct and indirect costs updated to 2011. The introduction of the vaccination using RotaTeq® as a universal infant vaccination would increase the annual health care budget in 10.43 million euro and would result in a gain of an additional Quality Adjusted Life Year at a cost of 280,338€ from the healthcare system perspective and 210,167€ from the societal perspective. The model was stable to variable modifications. To sum up, according to our model and estimates, the introduction of a universal infant rotavirus vaccination with RotaTeq® in Spain would cause a large impact on the health care budget and would not be efficient unless significant variations in vaccine price, vaccine efficacy and/or utilities took place. Prev Med. 2014 Apr;61:116-21. 00917435 http://hdl.handle.net/20.500.12105/10090 24360847 10.1016/j.ypmed.2013.12.013 1096-0260 Preventive medicine Biomedical Cost–benefit analysis Mass vaccination Medical economics Rotavirus Technology assessment Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain